DermTech announced this week that it has raised $5.6 million in a Series B financing round, which it will use to commercialize its melanoma detection test using Life Technologies' OpenArray quantitative real-time PCR system and to establish a CLIA-certified lab facility in which to offer the assay.

The company has spent several years developing a melanoma identification test, which measures the expression of multiple gene targets in RNA extracted from skin samples collected using custom adhesive strips that non-invasively lift cells from suspicious lesions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.